- Home
- KULR vs CTSO Comparison
KULR vs CTSO Comparison
Compare KULR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KULR
- CTSO
- Stock Information
- Founded
- KULR 2013
- CTSO 1997
- Country
- KULR United States
- CTSO United States
- Employees
- KULR N/A
- CTSO N/A
- Industry
- KULR Electrical Products
- CTSO Medical/Dental Instruments
- Sector
- KULR Technology
- CTSO Health Care
- Exchange
- KULR Nasdaq
- CTSO Nasdaq
- Market Cap
- KULR 55.3M
- CTSO 51.6M
- IPO Year
- KULR N/A
- CTSO N/A
- Fundamental
- Price
- KULR $2.28
- CTSO $1.03
- Analyst Decision
- KULR Strong Buy
- CTSO Strong Buy
- Analyst Count
- KULR 1
- CTSO 3
- Target Price
- KULR $5.00
- CTSO $4.67
- AVG Volume (30 Days)
- KULR 53.2M
- CTSO 538.8K
- Earning Date
- KULR 11-13-2024
- CTSO 03-06-2025
- Dividend Yield
- KULR N/A
- CTSO N/A
- EPS Growth
- KULR N/A
- CTSO N/A
- EPS
- KULR N/A
- CTSO N/A
- Revenue
- KULR $9,700,738.00
- CTSO $37,739,531.00
- Revenue This Year
- KULR $3.70
- CTSO $9.20
- Revenue Next Year
- KULR $76.20
- CTSO $11.64
- P/E Ratio
- KULR N/A
- CTSO N/A
- Revenue Growth
- KULR 4.20
- CTSO 1.80
- 52 Week Low
- KULR $0.10
- CTSO $0.70
- 52 Week High
- KULR $5.49
- CTSO $1.59
- Technical
- Relative Strength Index (RSI)
- KULR 47.59
- CTSO 55.82
- Support Level
- KULR $2.24
- CTSO $1.00
- Resistance Level
- KULR $2.69
- CTSO $1.14
- Average True Range (ATR)
- KULR 0.57
- CTSO 0.09
- MACD
- KULR -0.21
- CTSO 0.01
- Stochastic Oscillator
- KULR 12.77
- CTSO 64.40
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems; artificial intelligence and Cloud computing; energy storage; and 5G communication technologies.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.